Ropes & Gray advised Sanofi on the transaction, and Goodwin Procter advised Vigil Neuroscience. Sanofi (Nasdaq: SNY) has made a $40 million strategic investment in Vigil…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
